B+
Bull case
25%
Probability
Target price
$3.40
+85.8% vs current
GANX
Gain TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.80
-1.6% vs current
B-
Bear case
30%
Probability
Target price
$0.80
-56.3% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+52.7
Score
AI commentary
This remains a cautious monitoring setup rather than a standard-conviction biotech thesis. The company has credible primary-source milestones around IND clearance, Phase 2 start, and a later 2026 data package, but the deterministic prior is neutral-to-soft, the 10-K's going-concern language keeps financing risk central, and the available peer set is only a loose public-market trading reference rather than a strong operating comp set [#8-K-2026-03-26] [#10-K-2026-03-26].
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-06-30eventFDA IND clearance for U.S. Phase 2 expansionHigh impact
Management said IND clearance is expected in 2Q26 to facilitate U.S. Phase 2 clinical development for GT-02287; hitting that regulatory step would validate the near-term development plan, while delay would likely pressure a thinly covered small-cap biotech setup [#8-K-2026-03-26].
2026-09-30catalystFinancing and going-concern overhang remains activeHigh impact
The 10-K says there is substantial doubt about the company's ability to continue as a going concern and that additional capital will be needed; with year-end cash, cash equivalents and marketable securities of $20.8 million, any financing or unfavorable runway update can materially cap upside before later-stage data arrive [#10-K-2026-03-26].
2026-09-30catalystGT-02287 Phase 2 start targeted for 3Q26High impact
The company said Phase 2 in Parkinson's disease is expected to begin in 3Q26, but the setup still depends on regulatory execution and operational follow-through; a clean start could improve sentiment, though it is more a de-risking step than proof of efficacy [#10-K-2026-03-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology